Evidence map›Paper›PMID 32724323›Full record

ReviewEvidence-based complementary and alternative medicine : eCAM2020

Effectiveness and Safety of Herbal Medicine for Atopic Dermatitis: An Overview of Systematic Reviews.

Chan-Young Kwon, Boram Lee, Suran Kim, Jaesuk Lee, Minjung Park, Namkwen Kim

Open access · hybridAbstract readReview
In one paragraph

Review in Evidence-based complementary and alternative medicine : eCAM, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. The immunomodulatory activity ofJournal of Taibah University Medical Sciences · 2024
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Chan-Young KwonDepartment of Oriental Neuropsychiatry, Dong-eui University College of Korean Medicine, 62 Yangjeong-ro, Busanjin-gu, Busan 47227, Republic of Korea.ORCID https://orcid.org/0000-0003-0068-9904
Boram LeeClinical Medicine Division, Korea Institute of Oriental Medicine, 1672 Yuseongdae-ro, Yuseong-gu, Daejeon 34054, Republic of Korea.ORCID https://orcid.org/0000-0003-1679-0644
Suran KimGuideline Center for Korean Medicine, National Institute for Korean Medicine Development, 173 Toegye-ro, Jung-gu, Seoul 04554, Republic of Korea.
Jaesuk LeeGuideline Center for Korean Medicine, National Institute for Korean Medicine Development, 173 Toegye-ro, Jung-gu, Seoul 04554, Republic of Korea.
Minjung ParkGuideline Center for Korean Medicine, National Institute for Korean Medicine Development, 173 Toegye-ro, Jung-gu, Seoul 04554, Republic of Korea.ORCID https://orcid.org/0000-0003-2219-9666
Namkwen KimGuideline Center for Korean Medicine, National Institute for Korean Medicine Development, 173 Toegye-ro, Jung-gu, Seoul 04554, Republic of Korea.ORCID https://orcid.org/0000-0001-6969-1231
National Development Institute of Korean Medicine · KRDong-Eui University · KRKorea Institute of Oriental Medicine · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesHerbal medicine (HM) is attracting attention for treating atopic dermatitis (AD). This overview was conducted to summarize and critically evaluate the current systematic reviews (SRs) on HM for the treatment of AD.

methodsThrough comprehensive searches, all relevant SRs on HM for AD published until May 2020 were included. The quality of included SRs was assessed using the AMSTAR-2 tool. Moreover, original randomized controlled trials (RCTs) included in the SRs were resynthesized to investigate the efficacy and safety of oral HM for AD. The quality of evidence for the main findings was evaluated using the GRADE approach.

resultsNine SRs were included in this overview. HM showed significantly better efficacy in terms of total effective rate (TER), itching and sleep symptom scores, quality of life, and the dose of topical treatment used compared with placebo. HM as a monotherapy and/or an adjunctive therapy to conventional medication (CM) showed significantly better results on the efficacy, symptom relief, and some laboratory parameters related to the inflammatory response. The methodological quality was generally low. When 58 original RCTs were reanalyzed, HM showed significantly lower SCORing Atopic Dermatitis (SCORAD) score and higher TER than the placebo or CM. In terms of the safety profile, HM was not significantly different from the placebo and was better than CM. The quality of evidence ranged from "moderate" to "very low."

conclusionThe results suggested that HM as a monotherapy or an adjunctive therapy is promising for the treatment of AD. However, due to low methodological quality and low quality of evidence, further rigorous, well-designed, high-quality SRs, and RCTs are needed to make clinical recommendations on HM use.

Identifiers

PMID32724323
PMCPMC7382724
OpenAlexW3042492025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.